On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

In this episode of The NBR Podcast with Simon Shepherd: Obesity. Conservatively, it's a two-billion-dollar problem. But the ...

The research, published in the Canadian Medical Association Journal (CMAJ) Monday, found that 32.7 per cent of Canadians ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...

An Ozempic user has revealed what they believe is a 'terrifying' side effect of upping their Ozempic dose. Falling into the category of GLP-1 medications, Ozempic is FDA-approved for type two diabetes ...

Weight Watchers went bankrupt in May, but now it promises it's trimmed the fat off its books and is ready to rejoin the ...

When telehealth executive Andrew Dudum received a email wishing him a happy Father’s Day last month, he took it as a sign of the strong relationship he’d cultivated with a key partner. He did not see ...